Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Living Cell Technologies ( (AU:1AI) ) just unveiled an announcement.
Algorae Pharmaceuticals has received a cash refund of $384,466.78 from the Australian Taxation Office under the R&D Tax Incentive program for its eligible research and development activities in 2025. This non-dilutive funding will bolster the company’s financial position and support its AI-driven drug discovery programs and commercial pipeline, reflecting its commitment to innovative pharmaceutical development.
More about Living Cell Technologies
Algorae Pharmaceuticals is an AI-enabled pharmaceutical development company that focuses on discovering and developing drug synergies for unmet medical needs. The company utilizes its proprietary AI platform, AlgoraeOS, which employs machine learning and deep neural networks to identify synergistic drug combinations with transformative therapeutic potential. Algorae collaborates with leading research institutions and pharmaceutical partners to accelerate the translation of AI-predicted therapies into clinical settings. It is publicly traded on the Australian Stock Exchange.
YTD Price Performance: 60.0%
Average Trading Volume: 3,626,218
Technical Sentiment Signal: Buy
Current Market Cap: A$28.71M
See more insights into 1AI stock on TipRanks’ Stock Analysis page.